



**Anxiety, depression and incident cognitive impairment in community-dwelling older adults**



Journal:	<i>Journal of the American Geriatrics Society</i>
Manuscript ID:	JAGS-1338-CI-Nov-10.R1
Manuscript Type:	Clinical Investigation
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Potvin, Olivier; Université de Sherbrooke, Faculté de médecine et des sciences de la santé; Centre de recherche de l'Hôpital Charles LeMoine, Axe santé mentale et vieillissement; Centre de recherche Université Laval Robert-Giffard, Axe neurosciences cliniques et cognitives</p> <p>Forget, Hélène; Université du Québec en Outaouais, Département de psychoéducation et de psychologie</p> <p>Grenier, Sébastien; Université de Sherbrooke, Faculté de médecine et des sciences de la santé; Centre de recherche de l'Hôpital Charles LeMoine, Axe santé mentale et vieillissement</p> <p>Preville, Michel; Université de Sherbrooke, Faculté de médecine et des sciences de la santé; Centre de recherche de l'Hôpital Charles LeMoine, Axe santé mentale et vieillissement</p> <p>Hudon, Carol; Université Laval, École de psychologie; Centre de recherche Université Laval Robert-Giffard, Axe neurosciences cliniques et cognitives</p>
Key Words:	anxiety, depression, Cognitive decline, sex differences, older adults

1  
2  
3 **Anxiety, depression and incident cognitive impairment in community-dwelling**  
4  
5  
6 **older adults**  
7  
8  
9

10  
11 Olivier Potvin, Ph.D.,<sup>1,2,3</sup> Hélène Forget, Ph.D.,<sup>4</sup> Sébastien Grenier, Ph.D.,<sup>1,2</sup>

12  
13 Michel Prévaille, Ph.D.,<sup>1,2</sup> and Carol Hudon, Ph.D.<sup>3,5</sup>  
14  
15

16  
17  
18 <sup>1</sup>Université de Sherbrooke, Sherbrooke, Québec, Canada; <sup>2</sup>Centre de recherche Hôpital Charles  
19 LeMoyne, Longueuil, Québec, Canada; <sup>3</sup>Centre de recherche Université Laval Robert-Giffard,  
20 Québec, Québec, Canada; <sup>4</sup>Université du Québec en Outaouais, Gatineau, Québec, Canada;  
21  
22

23 <sup>5</sup>Université Laval, Québec, Québec, Canada  
24  
25  
26  
27  
28  
29  
30  
31

32 **Corresponding author:**  
33

34 Dr. Olivier Potvin  
35

36  
37 Centre de recherche Université Laval Robert-Giffard  
38 2601, de la Canardière  
39 Québec (Québec)  
40 CANADA G1J 2G3  
41

42  
43 Phone: (418) 663-5000 ext. 6857

44 Fax: (418) 663-5971

45 Email: [Olivier.Potvin@crulrg.ulaval.ca](mailto:Olivier.Potvin@crulrg.ulaval.ca)  
46  
47  
48  
49  
50

51 **Running head:** Anxiety, depression and cognitive decline  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

**OBJECTIVES:** To examine in men and women the independent associations of anxiety and depression with incident cognitive impairment and to examine the association of cognitive impairment no dementia (CIND) and incident cognitive impairment with incident anxiety/depression.

**DESIGN:** Prospective cohort study.

**SETTING:** General community.

**PARTICIPANTS:** Population-based sample of 1942 individuals aged 65 to 96.

**MEASUREMENTS:** Two structured interviews separated by 12 months evaluated anxiety and mood symptoms/disorders according to DSM-IV criteria. Incident cognitive impairment was defined by no CIND at baseline, a follow-up Mini-Mental State Examination score of at least two points below baseline and below the 15th percentile according to normative data. The associations for incident cognitive impairment and incident anxiety or depression were assessed by logistic regressions adjusted for potential confounders.

**RESULTS:** Incident cognitive impairment was, independently of depression, associated with baseline anxiety disorders (odds ratio: 6.27, 95% CI: 1.39-28.29) in men and anxiety symptoms (2.14, 1.06-4.34) in women. Moreover, the results indicated that depression disorders (8.87, 2.13-36.96) in men and anxiety symptoms in women (4.31, 1.74-10.67) were particularly linked to incident amnesic cognitive impairment while anxiety disorders (12.01, 1.73-83.26) in men was especially associated with incident non-amnesic cognitive impairment. CIND at baseline or incident cognitive impairment were not associated with incident anxiety or depression.

**CONCLUSION:** Anxiety and depression appear to have different relations with incident cognitive impairment according to sex and the nature of cognitive impairment. Anxiety in older

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

adults should receive particular attention by clinicians since it can be shortly followed by incident cognitive impairment.

For Review Only

## INTRODUCTION

Anxiety and depression are common psychiatric symptomatologies in the elderly population. In the community-dwelling elders, the prevalence rates are up to 15% for anxiety disorders and 52% for anxiety symptoms.<sup>1</sup> Regarding mood disorders (including major depressive disorder and minor depression) the prevalence rate is up to 35%.<sup>2</sup> Previous studies with cognitively intact elders indicated that depressive symptomatology often precedes cognitive decline<sup>3-7</sup> and this association may be more pronounced in men than in women.<sup>3, 8-10</sup> Recent studies also found that depressive symptomatology was related to incident cognitive impairment no dementia (CIND), but the relation was stronger for incident amnesic CIND (i.e. CIND that includes memory impairment).<sup>5</sup> Moreover, other results demonstrated that depressive symptoms occur along with cognitive decline in elders who develop Alzheimer's disease (AD), suggesting that depressive symptoms may be an early reaction to perceived cognitive decline rather than a "prodrome".<sup>11</sup>

There is evidence that anxiety, measured by dimensional scales or lists of symptoms, may precede cognitive decline in elders,<sup>12-14</sup> but there are controversial results.<sup>15-17</sup> Since anxiety and mood disorders have a high rate of comorbidity and given that scales assessing anxiety and depression are correlated,<sup>18-21</sup> it is essential to assess simultaneously both anxiety and depression in order to examine their independent associations with cognitive decline. At the moment very few community studies have assessed whether anxiety and depression are independently related to cognitive decline. Bierman *et al.* observed that a high anxiety level was not predictive of cognitive decline and only had a temporary effect on cognitive functioning.<sup>16, 22</sup> Palmer *et al.* showed that in elders with mild cognitive impairment (MCI), a group of symptoms labeled as "anxiety" (indecision, persistent worrying, anxiety, and social withdrawal), but not mood symptoms (dysphoria, suicidal ideation/thoughts of death, feelings of guilt, and appetite disturbance), were linked to incident AD. On the other hand, in elders with intact cognitive

1  
2  
3 functioning, mood, but not anxiety symptoms, were associated with incident AD.<sup>13</sup> Gallacher *et*  
4  
5 *al.* observed that in cognitively intact older men, trait anxiety (i.e. relatively stable individual  
6  
7 differences in anxiety-proneness) was related with incident CIND independently of depressive  
8  
9 symptoms, but not with dementia.<sup>14</sup>  
10  
11

12  
13 The main objective of the present study was to assess the independent relations of anxiety  
14  
15 disorders and mood disorders with the incidence of cognitive impairment in community-dwelling  
16  
17 older adults. Since clinically significant anxiety symptoms in elders are less likely to fully meet  
18  
19 all DSM-IV criteria for anxiety disorders,<sup>23-25</sup> anxiety symptoms not meeting all DSM-IV criteria  
20  
21 were also examined. The second objective was to examine whether CIND precedes the onset of  
22  
23 anxiety and depression symptomatologies and whether incident cognitive impairment occurs  
24  
25 along with incident anxiety/depression. Furthermore, since previous studies suggested that  
26  
27 depression was more strongly associated with incident cognitive impairment in men and with  
28  
29 amnesic incident cognitive impairment, sex differences were examined and the associations were  
30  
31 assessed for amnesic and non-amnesic cognitive impairment.  
32  
33  
34  
35  
36  
37  
38

## 39 METHODS

### 40 41 **ESA Study**

42  
43 Data come from the *Enquête sur la santé des aînés* (ESA Study; in English, Study on Elders'  
44  
45 Health), a population-based study on elders' mental health.<sup>26</sup> The aim of the ESA study was to  
46  
47 assess the prevalence and incidence of many psychiatric disorders (mood disorders and anxiety  
48  
49 disorders) in the province of Québec, Canada. In 2005-2006, a random sample (n = 2811) of  
50  
51 community-dwelling French-speaking adults (95% of the Québec population speaks French)<sup>27</sup>  
52  
53 aged 65 years or older and living in the province of Québec, Canada, were recruited. The  
54  
55 sampling frame of the study used a random dialing method with a stratification of proportional  
56  
57  
58  
59  
60

1  
2  
3 sample of households according to geographical areas (metropolitan, urban, and rural) and the 16  
4  
5 administrative regions of the Québec's province. A random sampling method was also used to  
6  
7 select only one elder within the household. The response rate was 76.5% at the first interview.  
8  
9

10 Data were collected through in-home structured interviews conducted by trained research  
11  
12 nurses who received 2 days of training by the principal investigator (M.P.) in the administration  
13  
14 of the ESA computer-assisted questionnaire (ESA-Q). The ESA-Q comprises many  
15  
16 questionnaires including an adapted version of the DSM-IV mood and anxiety disorders sections  
17  
18 of the Diagnostic Interview Schedule and Composite International Diagnostic Interview, which  
19  
20 have demonstrated satisfactory reliability and validity to establish psychiatric diagnoses.<sup>28-30</sup>  
21  
22 Cognitive functioning was assessed with the Mini-Mental State Examination (MMSE).<sup>31</sup> To  
23  
24 ensure the validity of the data in the ESA study, the complete interview was done only with  
25  
26 participants who scored 22 or higher on the MMSE (26 participants had a MMSE score <22 at  
27  
28 baseline). The follow-up interview occurred approximately 12 months after the baseline  
29  
30 interview (mean: 12.5 SD: 1.4). Data from the ESA study were linked with medical records from  
31  
32 the *Régie de l'assurance maladie du Québec* (RAMQ; Québec's public health insurance plan).  
33  
34 All Québec residents are registered to the RAMQ coverage. The respondents were offered a \$15  
35  
36 compensation for their participation. Written informed consent was obtained at the beginning of  
37  
38 the interview from all participants. The research procedures were previously reviewed and  
39  
40 authorized by the ethics committee of the *Institut universitaire de gériatrie de Sherbrooke*.  
41  
42  
43  
44  
45  
46  
47

### 48 **Study Sample**

49  
50 Figure 1 shows the flow chart of study enrollment and exclusion criteria. Among the 2785  
51  
52 participants who received the psychiatric interview at baseline, 47 died and 525 were not  
53  
54 interviewed at follow-up. Medical records from the RAMQ were available for 2010 individuals  
55  
56 and only these participants were included in the present study. The missing data from the RAMQ  
57  
58  
59  
60

1  
2  
3 records was due to refusal of consent to provide medical records, moving outside Québec, or  
4  
5 having additional drug insurance. According to the medical records covering one year before the  
6  
7 baseline to the follow-up interview, participants who received a diagnosis of dementia and/or  
8  
9 were taking an approved pharmacological treatment for dementia (memantine, donepezil,  
10  
11 galantamine, or rivastigmine) were excluded from the sample (n = 41). Moreover, nine  
12  
13 participants were excluded because education level was unknown and eighteen others were  
14  
15 excluded because their interview was incomplete. Thus, 1942 participants were included in the  
16  
17 present study. For the second objective of the present study (analyses on the psychiatric interview  
18  
19 at follow-up), data was available for 1930 participants since 12 participants did not receive the  
20  
21 complete evaluation at follow-up because they had a follow-up MMSE score below 22.  
22  
23  
24  
25

### 26 27 **Psychiatric variables**

28  
29 In both interviews, all psychiatric symptoms were identified for the 12-month period preceding  
30  
31 the interview according to DSM-IV criteria.<sup>32</sup> Depression included major depressive episode and  
32  
33 depressive disorder not otherwise specified. Subjects reporting that depressive symptoms began  
34  
35 after the loss of a loved one were not considered as having depression. Anxiety disorders  
36  
37 comprised specific phobia, social phobia, agoraphobia, panic disorder, and generalized anxiety  
38  
39 disorder. Anxiety and depressive disorders were defined as syndromes meeting all DSM-IV  
40  
41 criteria. Participants having at least one essential symptom of a DSM-IV anxiety or depressive  
42  
43 disorder without meeting full criteria were considered as having symptoms. For example,  
44  
45 minimal criteria for symptoms of panic disorder were “a discrete period of intense fear or  
46  
47 discomfort, in which one (or more) symptom for panic attack developed abruptly” and minimal  
48  
49 criteria for generalized anxiety disorder symptoms were “excessive anxiety and worry occurring  
50  
51 more days than not for at least one month”. All minimal criteria for anxiety disorders symptoms  
52  
53 (also called subclinical symptoms) were published elsewhere.<sup>33</sup> Minimal criteria for depression  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 symptoms were defined as two weeks of depressed mood or marked diminished interest/pleasure  
4  
5 in daily activities. Moreover, symptoms were separated into two categories: clinically significant  
6  
7 (*symptoms +*) and not clinically significant (*symptoms -*). Symptoms were considered clinically  
8  
9 significant when one of the following criteria was met: 1) participants consulted or were thinking  
10  
11 about consulting a health professional for their symptoms, 2) the symptoms produced major  
12  
13 distress, or 3) caused impairment in any of the following areas of functioning: activities of daily  
14  
15 living, social activities, and relationships with others. Finally, participants were considered  
16  
17 having incident psychiatric symptoms/disorders only if they displayed no such symptom at  
18  
19 baseline.  
20  
21  
22  
23

### 24 **Cognitive impairment**

25  
26 The criterion used for CIND at baseline was similar to that of studies from the Kungsholmen  
27  
28 Project group<sup>34-35</sup> and was defined as a MMSE score below the 15<sup>th</sup> percentile according to  
29  
30 normative data for age, education and sex,<sup>36</sup> which is equivalent to a score below one standard  
31  
32 deviation in a normal distribution. Incident cognitive impairment was defined as no CIND at  
33  
34 baseline with a follow-up MMSE score below the 15<sup>th</sup> percentile according to norms for age,  
35  
36 education and sex.<sup>36</sup> Since it was previously established that a reliable change in MMSE score for  
37  
38 short intervals consisted in a loss of at least 2 points,<sup>37</sup> a loss of 2 MMSE points between baseline  
39  
40 and follow-up was required in addition to a MMSE score below the 15<sup>th</sup> percentile to meet  
41  
42 incident cognitive impairment criteria. Cognitive impairment was labeled as “general cognitive  
43  
44 impairment” since the MMSE assesses general cognitive functioning. Moreover, based on  
45  
46 previous findings,<sup>5, 38</sup> amnesic and non-amnesic subtypes of cognitive impairment were  
47  
48 identified. The 3-word recall task of the MMSE was reported to be an adequate measure of  
49  
50 episodic memory in epidemiologic studies.<sup>39</sup> Thus, cognitive impairment with a score of 0 or 1  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 out of 3 on the 3-word recall task of the MMSE was considered a cognitive impairment of the  
4  
5 amnestic type.  
6

### 7 8 **Covariates**

9  
10 Potential confounders included age, education, sex, geographical living areas (urban/rural),  
11  
12 psychotropic drug use, vascular conditions, chronic diseases, and brain disorders. Psychotropic  
13  
14 drug use was assessed by the RAMQ medical records and drugs were coded according to the  
15  
16 American Hospital Formulary Service.<sup>40</sup> Psychotropic drug use was defined as one prescription  
17  
18 during the year between the baseline and the follow-up interview. The number of chronic  
19  
20 diseases according to the International Classification of Diseases (ICD-10) was measured by  
21  
22 asking participants at baseline if they had any of the following chronic health problems: arthritis  
23  
24 or rheumatism, eye diseases, backache or spinal problems, digestive problems, thyroid disorders,  
25  
26 other metabolic disorders, anemia, hypercholesterolemia, asthma or emphysema or chronic  
27  
28 bronchial diseases, liver diseases, kidney or urinary problems, skin diseases, migraine or frequent  
29  
30 headaches, schizophrenia and other forms of psychosis. A cardiovascular condition score was  
31  
32 computed using the RAMQ medical records and by asking participants at baseline if they had  
33  
34 high blood pressure, diabetes, and heart diseases. The score was the total of these three health  
35  
36 problems. The presence of brain disorders was assessed by the RAMQ medical records covering  
37  
38 the year between the baseline and the follow-up interview for the following disorders:  
39  
40 cerebrovascular disease, brain trauma/tumor/infections, multiple sclerosis, Parkinson's disease,  
41  
42 and epilepsy.  
43  
44  
45  
46  
47  
48  
49

### 50 51 **Statistical analysis**

52  
53 For the analyses on incident cognitive impairment, participants with cognitive impairment  
54  
55 at baseline were discarded. Characteristics differences between participants with incident  
56  
57 cognitive impairment and those with intact cognitive functioning were evaluated with *t*-tests and  
58  
59  
60

1  
2  
3 chi-squares. The associations between incident cognitive impairment and anxiety/depression  
4  
5 were first assessed by crude odds ratio (OR) with 95% confidence intervals (CI). Then, the  
6  
7 independent associations were assessed by adjusted ORs computed by a logistic regression with  
8  
9 incident cognitive impairment as the predicted variable, anxiety and depression at baseline as  
10  
11 predictors, and was adjusted for age, education, sex, geographical living areas, MMSE score at  
12  
13 baseline, psychotropic drug use, brain disorders, cardiovascular conditions score and chronic  
14  
15 diseases. Anxiety was coded as disorders, *symptoms +*, *symptoms -*, or absent. The same coding  
16  
17 was done for depression, but since very few cases of symptoms were identified, the categories  
18  
19 *symptoms +* and *symptoms -* were merged. All other variables were categorized as described in  
20  
21 the previous section.  
22  
23  
24  
25  
26

27 The associations between incident anxiety or depression and cognitive impairment were  
28  
29 assessed for both cognitive impairment at baseline (CIND) and incident cognitive impairment by  
30  
31 crude and adjusted ORs. To allow a sufficient number of cases, disorders and symptoms  
32  
33 categories were grouped. For the analysis on incident anxiety, participants with anxiety at  
34  
35 baseline were discarded, cognitive impairment was used as predictor, and the OR was adjusted  
36  
37 for depression at baseline. The equivalent was conducted for the analysis on incident depression.  
38  
39 ORs were also adjusted for age, education, sex, geographical living areas, psychotropic drug use,  
40  
41 brain disorders, vascular conditions score and chronic diseases. Finally, sex differences for all  
42  
43 ORs were examined with Breslow-Day tests for homogeneity of odds ratios. Statistical  
44  
45 assumptions were verified and analyses were performed using SPSS software (16.0) with the  
46  
47 alpha level set at a two-tailed 5%.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

At baseline, 174 participants met the criterion for CIND. At follow-up, 112 participants displayed incident cognitive impairment. Table 1 shows the characteristics of the participants with incident general cognitive impairment and participants with intact cognitive functioning. Compared to participants with intact cognitive functioning, participants with incident cognitive impairment were older, had a lower MMSE score at baseline and a higher number of chronic diseases. Moreover, the proportion of participants with incident cognitive impairment was lower in urban than in rural areas. Finally, the mean difference between MMSE scores at baseline and at follow-up was -3.5 for participants with incident cognitive impairment and 0.1 for participants with intact cognitive functioning; this difference was statistically significant.

A significant sex difference ( $p = .001$ ) was observed for the association between incident cognitive impairment and anxiety disorders. Therefore, ORs for incident cognitive impairment were computed separately for men and women. Table 2 indicates, for men and women, the associations of baseline anxiety and depression with incident cognitive impairment. In women, anxiety *symptoms* - were significantly associated with general and amnesic incident cognitive impairment. In men, anxiety disorders at baseline were significantly linked with incident general and non-amnesic cognitive impairment while depressive disorders were significantly related to incident amnesic cognitive impairment. In both men and women, no case of depressive symptoms displayed incident cognitive impairment.

Table 3 shows the associations of CIND at baseline and incident cognitive impairment with incident anxiety or depression. No significant sex difference was observed in the ORs between incident anxiety or depression and cognitive impairment. CIND at baseline and incident cognitive impairment were not significantly related to incident depression or anxiety and these results were not influenced by the nature of the cognitive impairment (amnesic vs non-amnesic).

## DISCUSSION

The present study aimed to examine in community-dwelling older men and women the independent associations of anxiety and depression assessed by DSM-IV criteria with the incidence of cognitive impairment. In women, anxiety symptoms not clinically significant were found to be associated with incident general cognitive impairment and the results suggested that this association was specific to incident amnesic cognitive impairment. In men, anxiety disorders and depressive disorders were both related to incident cognitive impairment. The results also suggested that anxiety disorders were especially linked to incident non-amnesic cognitive impairment while depressive disorders were specifically related to incident amnesic, but not non-amnesic, cognitive impairment. Moreover, the relations of cognitive impairment with incident anxiety and depression were investigated. CIND at baseline and incident cognitive impairment were not significantly linked to incident anxiety or depression. Together, these results suggest that anxiety, independently of depression, is associated with incident cognitive impairment and that the relations of anxiety and depression with incident cognitive impairment differ according to sex and the nature of the cognitive impairment.

### *Anxiety and cognitive decline*

Previous results support a cross-sectional relationship in older adults between anxiety and cognitive impairment.<sup>22, 33, 41-42</sup> The present study indicated that anxiety, independently of depression, is often followed by cognitive decline within a year in older adults with intact cognitive functioning. Moreover, our results suggest that anxiety does not rise along with incident cognitive impairment or follow CIND. These findings agree with previous ones indicating that anxiety increases the risk of cognitive decline or AD.<sup>12-14</sup> Among these studies, Palmer *et al.* used a 3-year follow-up and showed that a group of symptoms labeled as “anxiety” (indecision,

1  
2  
3 persistent worrying, anxiety, and social withdrawal) increased the risk of AD in elders with MCI,  
4  
5 but not in elders with intact cognitive functioning. It could be debated whether symptoms of  
6  
7 indecision and social withdrawal are truly anxiety symptoms, nevertheless, Palmer *et al.* reported  
8  
9 that persistent worrying alone had a fivefold increased risk of AD in elders with MCI compared  
10  
11 to elders with MCI without persistent worrying.<sup>13</sup> Using a much longer follow-up (17 years),  
12  
13 Gallacher *et al.* observed in a sample of older men that trait anxiety increased the risk of CIND.<sup>14</sup>  
14  
15  
16 Despite these results revealing links between anxiety and cognitive decline, other previous  
17  
18 studies did not find any support for this hypothesis.<sup>15-17</sup> In fact, one study did not find that high  
19  
20 anxiety level was linked to incident cognitive decline<sup>16</sup> and two others found that high anxiety  
21  
22 level in elders with MCI or questionable dementia decreased the risk of converting to AD.<sup>15, 17</sup>  
23  
24 Since all of these studies used diverse populations, follow-ups lengths, neuropsychological  
25  
26 assessments, and anxiety assessments, it is difficult to draw a fair conclusion. Nevertheless, it is  
27  
28 likely that the relation between anxiety and cognitive decline is modified by multiple factors and  
29  
30 further studies are needed to develop a better comprehension of this relation.  
31  
32  
33  
34  
35

### 36 *Anxiety and depressive symptoms not meeting criteria for disorders*

37  
38 Many authors have pointed out that anxiety in older adults differs from that in younger adults and  
39  
40 that clinically significant anxiety symptoms in elders are less likely to fully meet all DSM-IV  
41  
42 criteria for anxiety disorders than in younger adults.<sup>23-25</sup> In addition, a study showed that elders  
43  
44 with anxiety symptoms not meeting all DSM-III criteria for anxiety disorders did not differ in  
45  
46 terms of disability, well-being, and medication use from elders with anxiety disorders.<sup>43</sup> In line  
47  
48 with these results, a recent study suggested that older adults with anxiety symptoms not fully  
49  
50 meeting DSM-IV criteria were similar in their health characteristics compared to older adults  
51  
52 with anxiety symptoms fully meeting DSM-IV criteria.<sup>44</sup> Recent data also showed that symptoms  
53  
54 of generalized anxiety disorders not meeting all DSM-IV criteria were associated to CIND.<sup>45</sup> In  
55  
56  
57  
58  
59  
60

1  
2  
3 the present study, we observed that anxiety symptoms that do not meet DSM-IV criteria and that  
4  
5 are not clinically significant (i.e. not producing major distress or altering functioning), were  
6  
7 associated with incident cognitive impairment in women. Moreover, contrasting with the results  
8  
9 on anxiety, the results on depression revealed that symptoms that do not meet DSM-IV criteria  
10  
11 were not common in our sample and they were even less common before incident cognitive  
12  
13 impairment since no participant with depression symptoms displayed incident cognitive  
14  
15 impairment. These findings strengthen the idea that anxiety symptoms not meeting DSM-IV  
16  
17 criteria are not negligible in older adults and that these symptoms should receive a particular  
18  
19 attention from clinicians.  
20  
21  
22  
23

#### 24 Potential mechanisms

25  
26 Many potential mechanisms could account for the association between anxiety/depression and  
27  
28 incident cognitive impairment. First, depression is linked to higher glucocorticoid levels<sup>46</sup> and it  
29  
30 was suggested that chronic exposure to glucocorticoid promotes neurons' death.<sup>47</sup> This  
31  
32 explanation is known as the neurotoxicity hypothesis and has received extensive attention in the  
33  
34 last decade (for a review on the topic see <sup>48</sup>). Previous studies also indicated that older adults with  
35  
36 anxiety disorders display elevated cortisol level.<sup>49-50</sup> Thus, it is probable that the neurotoxicity  
37  
38 hypothesis also applies to some anxiety disorders. Second, it is possible that anxiety and  
39  
40 depression are consequences of an ongoing brain disease such as AD or a vascular pathology,  
41  
42 altering normal brain functioning and leading to cognitive decline. A third explanation is that  
43  
44 anxiety and depression may be risk factors for incident cognitive impairment only in the presence  
45  
46 of other characteristics, for example a specific gene variant.<sup>7</sup> Fourth, as described earlier, anxiety  
47  
48 and depression may be a reaction to early cognitive decline. While the present results showed that  
49  
50 CIND and incident cognitive impairment were not linked to incident anxiety or depression, it is  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 possible that older adults with normal cognitive functioning, as measured by neuropsychological  
4 tests, perceive cognitive problems in their daily activities.  
5  
6

### 7 *Sex differences*

8  
9  
10 One of the main findings in the current study is that important differences between men and  
11 women were outlined. Depression was linked to incident cognitive impairment only in men.  
12  
13 Anxiety was differently related to incident cognitive impairment according to sex since it was  
14  
15 linked with disorders and symptoms, in men and in women respectively. Sex differences were  
16  
17 reported in many previous studies on the relations of anxiety and depression with cognitive  
18  
19 functioning or decline. In a recent cross-sectional study, we observed that generalized anxiety  
20  
21 disorders symptoms were linked to CIND in older men, but not in older women.<sup>45</sup> Previous  
22  
23 studies also observed that depression predicted the onset of dementia or cognitive decline in men,  
24  
25 but not in women.<sup>3, 8-10</sup> Many hypotheses were proposed to account for these discrepancies. First,  
26  
27 biological differences could be an explanation since estrogen might be a neuroprotective agent as  
28  
29 it enhances cognitive functioning in animal models.<sup>51-52</sup> However, its protective effect on  
30  
31 cognitive decline and dementia in humans is controversial.<sup>53-54</sup> Second, it was proposed that a  
32  
33 vascular pathology accentuating cognitive decline may underlies depression in men.<sup>9</sup> However,  
34  
35 other studies indicated that sex differences in the association between depression and cognitive  
36  
37 decline was not explained by vascular factors.<sup>3, 10</sup> Third, another explanation resides in the  
38  
39 different ways men and women tend to report their symptoms.<sup>10</sup> Compared to women, men are  
40  
41 usually less willing to admit their symptoms.<sup>55</sup> This difference may result in an underestimation  
42  
43 of psychiatric symptoms in men and an overestimation in women, leading to a higher number of  
44  
45 false-positives in women and diluting the association in this group.<sup>10</sup> It is also possible that  
46  
47 psychiatric symptoms preceding cognitive decline are reported in men as more severe symptoms  
48  
49 than in women. This last hypothesis provides a parsimonious explanation to account for the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 present results on anxiety. If anxiety has the same effect in men and in women, this hypothesis  
4  
5 explains why the least severe symptoms of anxiety in women and the most severe anxiety  
6  
7 symptoms in men were both linked to cognitive decline in the present study.  
8  
9

#### 10 *Strengths and limits of the study*

11  
12 There are several strengths and original contributions in the present study. First, it uses a large  
13  
14 sample of community-dwelling older adults, randomly selected, and with a good response rate  
15  
16 and thus, preventing potential selection biases. Second, the examination of sex differences and  
17  
18 anxiety symptoms not fully meeting DSM-IV criteria revealed important patterns of results and  
19  
20 these factors should be considered in future studies assessing the links between anxiety and  
21  
22 cognitive functioning. Third, unlike previous studies on the relations of anxiety with cognitive  
23  
24 decline or dementia which used brief dimensional scales or lists of symptoms,<sup>12-17</sup> the present  
25  
26 study used DSM-IV criteria for anxiety disorders to assess anxiety symptoms. The DSM-IV  
27  
28 criteria are standard and widely used. Therefore, they facilitate the comparison with future  
29  
30 studies. This is an advantage over previous studies using uncommon anxiety assessments, which  
31  
32 have major differences, and thus, renders the comparison between studies difficult. Finally, many  
33  
34 potential socio-demographic and health-related confounders were taken into account in the  
35  
36 statistical analyses of the present study.  
37  
38  
39  
40  
41  
42

43 The present study also has limitations. First, neuropsychological assessment was based on  
44  
45 the MMSE, which is a screening instrument for general cognitive functioning. Therefore, this  
46  
47 instrument does not adequately cover all cognitive functions (e.g. executive functioning) and  
48  
49 different results could have been observed with an extensive neuropsychological battery. A more  
50  
51 exhaustive neuropsychological evaluation is suitable for future studies on the relations between  
52  
53 anxiety and incident cognitive impairment. Second, despite the fact that we used a large sample  
54  
55 of older adults and that the examination of sex differences yielded interesting findings, the  
56  
57  
58  
59  
60

1  
2  
3 separated analyses for men and women had the cost to reduce the number of cases with  
4  
5 psychiatric symptoms. This was particularly notable in men because there were less male than  
6  
7 female participants and the prevalence of psychiatric symptoms in men was lower than in  
8  
9 women. Moreover, the analyses of the sex differences and the nature of the cognitive  
10  
11 impairments were exploratory. Therefore, the present findings should be interpreted with caution  
12  
13 and need to be replicated. Third, despite the fact that the extent of cognitive decline within 12  
14  
15 months in participants with incident cognitive impairment was relatively substantial (mean loss  
16  
17 of 3.5 MMSE points), the present study had a single follow-up and it did not evaluate dementia.  
18  
19 Hence, it is unknown whether participants with incident cognitive impairment remained stable,  
20  
21 further declined or recovered afterwards. Future studies on anxiety and cognitive functioning  
22  
23 with multiple follow-ups are suitable. Fourth, the data used in the present study did not allow to  
24  
25 investigate the underlying mechanisms of the associations between anxiety/depression and  
26  
27 incident cognitive impairment.

28  
29  
30  
31  
32  
33  
34 In summary, our results strengthened the idea that anxiety, independently of depression, is  
35  
36 associated with incident cognitive impairment in older adults. The results also suggest that this  
37  
38 relation is modified by sex as well as the nature of the cognitive impairment and that anxiety  
39  
40 symptoms not meeting DSM-IV criteria should not be overlooked in older adults. Anxiety in  
41  
42 older adults should receive particular attention by clinicians since it can be shortly followed by  
43  
44 incident cognitive impairment. Anxiety could be a potential target for the prevention and early  
45  
46 treatment of cognitive decline.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Bryant C, Jackson H, Ames D. The prevalence of anxiety in older adults: methodological issues and a review of the literature. *J Affect Disord.* 2008;109: 233-250.
2. Beekman AT, Copeland JR, Prince MJ. Review of community prevalence of depression in later life. *Br J Psychiatry.* 1999;174: 307-311.
3. Ng TP, Niti M, Zaw MH, Kua EH. Depressive symptoms and incident cognitive impairment in cognitively well-functioning older men and women. *J Am Geriatr Soc.* 2009;57: 1058-1063.
4. Lopez OL, Jagust WJ, Dulberg C, *et al.* Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. *Arch Neurol.* 2003;60: 1394-1399.
5. Kohler S, van Boxtel MP, van Os J, *et al.* Depressive symptoms and cognitive decline in community-dwelling older adults. *J Am Geriatr Soc.* 2010;58: 873-879.
6. Sachs-Ericsson N, Joiner T, Plant EA, Blazer DG. The influence of depression on cognitive decline in community-dwelling elderly persons. *Am J Geriatr Psychiatry.* 2005;13: 402-408.
7. Geda YE, Knopman DS, Mrazek DA, *et al.* Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. *Arch Neurol.* 2006;63: 435-440.
8. Cervilla JA, Prince M, Joels S, Mann A. Does depression predict cognitive outcome 9 to 12 years later? Evidence from a prospective study of elderly hypertensives. *Psychol Med.* 2000;30: 1017-1023.

- 1  
2  
3 9. Fuhrer R, Dufouil C, Dartigues JF. Exploring sex differences in the relationship between  
4  
5 depressive symptoms and dementia incidence: prospective results from the PAQUID  
6  
7 Study. *J Am Geriatr Soc.* 2003;51: 1055-1063.  
8  
9
- 10 10. Dal Forno G, Palermo MT, Donohue JE, Karagiozis H, Zonderman AB, Kawas CH.  
11  
12 Depressive symptoms, sex, and risk for Alzheimer's disease. *Ann Neurol.* 2005;57: 381-  
13  
14 387.  
15  
16
- 17 11. Amieva H, Le Goff M, Millet X, *et al.* Prodromal Alzheimer's disease: successive  
18  
19 emergence of the clinical symptoms. *Ann Neurol.* 2008;64: 492-498.  
20  
21
- 22 12. Sinoff G, Werner P. Anxiety disorder and accompanying subjective memory loss in the  
23  
24 elderly as a predictor of future cognitive decline. *Int J Geriatr Psychiatry.* 2003;18: 951-  
25  
26 959.  
27  
28
- 29 13. Palmer K, Berger AK, Monastero R, Winblad B, Backman L, Fratiglioni L. Predictors of  
30  
31 progression from mild cognitive impairment to Alzheimer disease. *Neurology.* 2007;68:  
32  
33 1596-1602.  
34  
35
- 36 14. Gallacher J, Bayer A, Fish M, *et al.* Does anxiety affect risk of dementia? Findings from  
37  
38 the Caerphilly Prospective Study. *Psychosom Med.* 2009;71: 659-666.  
39  
40
- 41 15. Liu HC, Wang PN, Wang HC, *et al.* Conversion to dementia from questionable dementia  
42  
43 in an ethnic Chinese population. *J Geriatr Psychiatry Neurol.* 2007;20: 76-83.  
44  
45
- 46 16. Bierman EJ, Comijs HC, Rijmen F, Jonker C, Beekman AT. Anxiety symptoms and  
47  
48 cognitive performance in later life: results from the longitudinal aging study Amsterdam.  
49  
50 *Aging Ment Health.* 2008;12: 517-523.  
51  
52
- 53 17. Devier DJ, Pelton GH, Tabert MH, *et al.* The impact of anxiety on conversion from mild  
54  
55 cognitive impairment to Alzheimer's disease. *Int J Geriatr Psychiatry.* 2009;24: 1335-  
56  
57 1342.  
58  
59  
60

- 1  
2  
3 18. Morin CM, Landreville P, Colecchi C, McDonald K, Stone J, Ling W. The Beck anxiety  
4 inventory: Psychometric properties with older adults. *Journal of Clinical Geropsychology*.  
5 1999;5: 19-29.  
6  
7
- 8  
9  
10 19. Beekman AT, de Beurs E, van Balkom AJ, Deeg DJ, van Dyck R, van Tilburg W.  
11 Anxiety and depression in later life: Co-occurrence and communality of risk factors. *Am J*  
12 *Psychiatry*. 2000;157: 89-95.  
13  
14
- 15  
16  
17 20. Lenze EJ. Comorbidity of depression and anxiety in the elderly. *Curr Psychiatry Rep*.  
18 2003;5: 62-67.  
19  
20
- 21  
22 21. Kessler RC, Berglund P, Demler O, *et al*. The epidemiology of major depressive disorder:  
23 results from the National Comorbidity Survey Replication (NCS-R). *JAMA*. 2003;289:  
24 3095-3105.  
25  
26  
27
- 28  
29 22. Bierman EJ, Comijs HC, Jonker C, Beekman AT. Effects of anxiety versus depression on  
30 cognition in later life. *Am J Geriatr Psychiatry*. 2005;13: 686-693.  
31  
32
- 33  
34 23. Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG. Anxiety disorders  
35 in older adults: a comprehensive review. *Depress Anxiety*. 2010;27: 190-211.  
36  
37
- 38  
39 24. Jeste DV, Blazer DG, First M. Aging-related diagnostic variations: need for diagnostic  
40 criteria appropriate for elderly psychiatric patients. *Biol Psychiatry*. 2005;58: 265-271.  
41  
42
- 43  
44 25. Palmer BW, Jeste DV, Sheikh JI. Anxiety disorders in the elderly: DSM-IV and other  
45 barriers to diagnosis and treatment. *J Affect Disord*. 1997;46: 183-190.  
46  
47
- 48  
49 26. Prévaille M, Boyer R, Grenier S, *et al*. The epidemiology of psychiatric disorders in  
50 Quebec's older adult population. *Can J Psychiatry*. 2008;53: 822-832.  
51  
52
- 53  
54 27. Statistics Canada. 2006 Census of Population [Statistics Canada Web site]. 2006.  
55
- 56  
57 28. Erdman HP, Klein MH, Greist JH, *et al*. A comparison of two computer-administered  
58 versions of the NIMH Diagnostic Interview Schedule. *J Psychiatr Res*. 1992;26: 85-95.  
59  
60


- 1  
2  
3 29. Robins LN, Helzer JE, Croughan J, Ratcliff KS. National Institute of Mental Health  
4  
5 Diagnostic Interview Schedule. Its history, characteristics, and validity. *Arch Gen*  
6  
7 *Psychiatry*. 1981;38: 381-389.  
8  
9  
10 30. Wittchen HU, Robins LN, Cottler LB, Sartorius N, Burke JD, Regier D. Cross-cultural  
11  
12 feasibility, reliability and sources of variance of the Composite International Diagnostic  
13  
14 Interview (CIDI). The Multicentre WHO/ADAMHA Field Trials. *Br J Psychiatry*.  
15  
16 1991;159: 645-653, 658.  
17  
18  
19 31. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for  
20  
21 grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12: 189-  
22  
23 198.  
24  
25  
26 32. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental*  
27  
28 *Disorders, Fourth Edition Text Revision (DSM-IV-TR)*. Washington DC: American  
29  
30 Psychiatric Publishing, Inc., 2000.  
31  
32  
33 33. Potvin O, Hudon C, Dion M, Grenier S, Prévaille M. Anxiety disorders, depressive  
34  
35 episodes and cognitive impairment no dementia in community-dwelling older men and  
36  
37 women. *Int J Geriatr Psychiatry*. 2010.  
38  
39  
40 34. Forsell Y, Palmer K, Fratiglioni L. Psychiatric symptoms/syndromes in elderly persons  
41  
42 with mild cognitive impairment. Data from a cross-sectional study. *Acta Neurol Scand*  
43  
44 *Suppl*. 2003;179: 25-28.  
45  
46  
47 35. Palmer K, Wang HX, Backman L, Winblad B, Fratiglioni L. Differential evolution of  
48  
49 cognitive impairment in nondemented older persons: results from the Kungsholmen  
50  
51 Project. *Am J Psychiatry*. 2002;159: 436-442.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
36. Hudon C, Potvin O, Turcotte MC, *et al.* Normalisation du Mini-Mental State Examination (MMSE) chez les Québécois francophones âgés de 65 ans et plus et résidant dans la communauté. *Can J Aging.* 2009;28: 347-357.
37. Hensel A, Angermeyer MC, Riedel-Heller SG. Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination. *J Neurol Neurosurg Psychiatry.* 2007;78: 1298-1303.
38. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. *Arch Neurol.* 2005;62: 1160-1163; discussion 1167.
39. Carcaillon L, Amieva H, Auriacombe S, Helmer C, Dartigues JF. A subtest of the MMSE as a valid test of episodic memory? Comparison with the Free and Cued Reminding Test. *Dement Geriatr Cogn Disord.* 2009;27: 429-438.
40. American Society of Health System Pharmacist. AHFS drug information. 2001.
41. Beaudreau SA, O'Hara R. Late-life anxiety and cognitive impairment: a review. *Am J Geriatr Psychiatry.* 2008;16: 790-803.
42. Beaudreau SA, O'Hara R. The association of anxiety and depressive symptoms with cognitive performance in community-dwelling older adults. *Psychol Aging.* 2009;24: 507-512.
43. de Beurs E, Beekman AT, van Balkom AJ, Deeg DJ, van Dyck R, van Tilburg W. Consequences of anxiety in older persons: its effect on disability, well-being and use of health services. *Psychol Med.* 1999;29: 583-593.
44. Grenier S, Prévile M, Boyer R, *et al.* The impact of DSM-IV symptom and clinical significance criteria on the prevalence estimates of subthreshold and threshold anxiety in the older adult population. *Am J Geriatr Psychiatry.* in press.

- 1  
2  
3 45. Potvin O, Hudon C, Dion M, Grenier S, Prévile M. Anxiety disorders, depressive  
4  
5 episodes and cognitive impairment no dementia in community-dwelling older men and  
6  
7 women. *Int J Geriatr Psychiatry*. in press.  
8  
9  
10 46. Burke HM, Davis MC, Otte C, Mohr DC. Depression and cortisol responses to  
11  
12 psychological stress: a meta-analysis. *Psychoneuroendocrinology*. 2005;30: 846-856.  
13  
14  
15 47. Sapolsky RM, Krey LC, McEwen BS. The neuroendocrinology of stress and aging: the  
16  
17 glucocorticoid cascade hypothesis. *Endocr Rev*. 1986;7: 284-301.  
18  
19  
20 48. Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan  
21  
22 on the brain, behaviour and cognition. *Nat Rev Neurosci*. 2009;10: 434-445.  
23  
24  
25 49. Chaudieu I, Beluche I, Norton J, Boulenger JP, Ritchie K, Ancelin ML. Abnormal  
26  
27 reactions to environmental stress in elderly persons with anxiety disorders: evidence from  
28  
29 a population study of diurnal cortisol changes. *J Affect Disord*. 2008;106: 307-313.  
30  
31  
32 50. Mantella RC, Butters MA, Amico JA, *et al*. Salivary cortisol is associated with diagnosis  
33  
34 and severity of late-life generalized anxiety disorder. *Psychoneuroendocrinology*.  
35  
36 2008;33: 773-781.  
37  
38  
39 51. Fader AJ, Hendricson AW, Dohanich GP. Estrogen improves performance of reinforced  
40  
41 T-maze alternation and prevents the amnesic effects of scopolamine administered  
42  
43 systemically or intrahippocampally. *Neurobiol Learn Mem*. 1998;69: 225-240.  
44  
45  
46 52. Singh M, Meyer EM, Millard WJ, Simpkins JW. Ovarian steroid deprivation results in a  
47  
48 reversible learning impairment and compromised cholinergic function in female Sprague-  
49  
50 Dawley rats. *Brain Res*. 1994;644: 305-312.  
51  
52  
53 53. Henderson VW. Action of estrogens in the aging brain: dementia and cognitive aging.  
54  
55 *Biochim Biophys Acta*. 2010;1800: 1077-1083.  
56  
57  
58  
59  
60



- 1  
2  
3 54. Barrett-Connor E, Laughlin GA. Endogenous and exogenous estrogen, cognitive function,  
4 and dementia in postmenopausal women: evidence from epidemiologic studies and  
5  
6  
7  
8  
9  
10  
11 55. Kessler RC, Brown RL, Broman CL. Sex differences in psychiatric help-seeking:  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- For Review Only



**Figure 1.** Flow chart of the study sample enrollment with white shapes representing exclusion criteria. CIND: cognitive impairment no dementia.

**Table 1 Characteristics of participants with and without incident general cognitive impairment**

Characteristic (N (%) or mean $\pm$ SD)	Incident general cognitive impairment (N = 112)	No cognitive impairment (N = 1656)	<i>p</i> <sup>a</sup>
Age	75.0 $\pm$ 5.6	73.6 $\pm$ 5.6	.010
Women	70 (62.5)	1161 (70.1)	.090
Education			
Primary or less	27 (24.1)	364 (21.9)	.725
Secondary	44 (39.3)	713 (43.1)	
Postsecondary	41 (36.6)	579 (35.0)	
Living in rural areas	49 (43.8)	540 (32.6)	.015
Psychotropic drug use	44 (39.3)	592 (35.7)	.450
Brain injury/disease	4 (3.6)	56 (3.4)	.915
Cardiovascular condition score	1.4 $\pm$ 0.9	1.2 $\pm$ 0.9	.133
Number of chronic diseases	2.6 $\pm$ 1.9	2.2 $\pm$ 1.7	.017
Baseline MMSE score	28.4 $\pm$ 1.2	28.9 $\pm$ 1.1	< .001
$\Delta$ MMSE score (baseline - follow-up)	-3.5 $\pm$ 1.6	0.1 $\pm$ 1.2	< .001

MMSE: Mini-mental state examination.

<sup>a</sup> Significance level from *t*-tests or chi-squares

**Table 2. Association of anxiety and depression at baseline with incident cognitive impairment in older men and women (N = 1772)**

		Incident cognitive impairment							
		General			Non-amnestic		Amnestic		
		Yes N (%)	No N (%)	Crude OR (95% CI)	Adjusted <sup>a</sup> OR (95% CI)	<i>p</i>	Adjusted <sup>a</sup> OR (95% CI)	<i>p</i>	Adjusted <sup>a</sup> OR (95% CI)
<b>Women</b>									
Anxiety									
DSM-IV	1 (1.4)	43 (3.7)	0.43 (0.06-3.20)	0.42 (0.06-3.18)	.403	0.62 (0.08-4.78)	.647	-	-
Symptoms +	8 (11.4)	92 (7.9)	1.61 (0.74-3.50)	1.49 (0.66-3.34)	.335	1.38 (0.51-3.77)	.525	1.69 (0.46-6.13)	.427
Symptoms -	11 (15.7)	99 (8.5)	2.06 (1.04-4.09)	2.14 (1.06-4.34)	.035	0.88 (0.26-2.97)	.838	4.31 (1.74-10.67)	.002
Depression									
DSM-IV	7 (10.0)	127 (10.9)	0.88 (0.40-1.97)	0.63 (0.27-1.48)	.292	0.62 (0.08-4.78)	.402	0.62 (0.17-2.27)	.473
Symptoms	0 (0.0)	24 (2.1)	-	-	-	-	-	-	-
<b>Men</b>									
Anxiety									
DSM-IV	4 (9.5)	6 (1.2)	8.48 (2.28-31.45)	6.27 (1.39-28.29)	.017	12.01 (1.73-83.26)	.012	4.78 (0.76-30.00)	.095
Symptoms +	3 (7.1)	22 (4.4)	1.73 (0.49-6.08)	1.83 (0.46-7.30)	.390	4.18 (0.79-22.13)	.093	0.68 (0.06-7.20)	.749
Symptoms -	0 (0.0)	22 (4.4)	-	-	-	-	-	-	-
Depression									
DSM-IV	5 (11.9)	25 (5.1)	2.50 (0.91-6.92)	3.29 (0.97-11.12)	.055	0.84 (0.07-9.64)	.887	8.87 (2.13-36.96)	.003
Symptoms	0 (0.0)	7 (1.4)	-	-	-	-	-	-	-

CI: confidence interval; OR: odds ratio; Symptoms +: anxiety symptoms clinically significant; Symptoms -: anxiety symptoms not clinically significant.  
<sup>a</sup> ORs and 95% CI were estimated by a logistic regression with incident cognitive impairment as predictor adjusted for age, education, geographical areas, MMSE score at baseline, psychotropic drug use, brain injury/disease, cardiovascular conditions, and chronic diseases. *p* values were obtained by Wald *F* statistics with *df* = 1.

**Table 3. Association of cognitive impairment with incident anxiety or depression in older adults (N = 1930)**

Cognitive impairment	Incident anxiety					Incident depression				
	Yes N (%)	No N (%)	OR (95% CI)	Adjusted <sup>a</sup> OR (95% CI)	<i>p</i>	Yes N (%)	No N (%)	OR (95% CI)	Adjusted <sup>a</sup> OR (95% CI)	<i>p</i>
CIND at baseline										
General	14 (7.3)	112 (8.1)	0.90 (0.51-1.61)	0.88 (0.49-1.59)	.678	12 (12.4)	125 (7.8)	1.68 (0.89-3.15)	1.59 (0.83-3.02)	.159
Non-amnestic	10 (5.3)	49 (3.7)	1.47 (0.73-2.96)	1.38 (0.67-2.85)	.379	6 (6.6)	65 (4.2)	1.61 (0.68-3.83)	1.36 (0.56-3.28)	.499
Amnestic	4 (2.2)	63 (4.7)	0.46 (0.17-1.27)	0.47 (0.17-1.32)	.153	6 (6.6)	60 (3.9)	1.75 (0.73-4.16)	1.90 (0.79-4.62)	.154
Incident										
General	11 (6.2)	71 (5.6)	1.13 (0.58-2.17)	1.10 (0.56-2.18)	.775	7 (8.2)	90 (6.1)	1.39 (0.62-3.10)	1.22 (0.53-2.77)	.639
Non-amnestic	6 (3.5)	38 (3.1)	1.15 (0.48-2.76)	1.00 (0.40-2.47)	.996	4 (4.9)	48 (3.3)	1.49 (0.52-4.24)	1.38 (0.48-3.98)	.553
Amnestic	5 (2.9)	33 (2.7)	1.10 (0.42-2.86)	1.20 (0.44-3.22)	.725	3 (3.7)	42 (2.9)	1.28 (0.39-4.21)	1.06 (0.31-3.67)	.924

CI: confidence interval; CIND: cognitive impairment no dementia; OR: odds ratio

<sup>a</sup> ORs and 95% CI were estimated by a logistic regression with incident anxiety or depression as predictors adjusted for anxiety or depression at baseline accordingly, age, education, sex, geographical areas, psychotropic drug use, brain injury/disease, cardiovascular conditions, chronic diseases. *p* values were obtained by Wald *F* statistics with *df* = 1.